Immunovant shared six-month off-treatment data for uncontrolled Graves' disease patients treated with batoclimab, showcasing positive responses and remission outcomes.
Results indicate potential disease modification with significant proportions of patients achieving normal thyroid function and ATD-free remission.
The study's findings could potentially change the treatment paradigm for uncontrolled Graves' disease patients.
First Disease-Modifying Therapy
Batoclimab shows potential as a disease-modifying therapy for uncontrolled Graves' disease patients.
Remission Rates
Around 80% of patients maintained normal thyroid function after six months off treatment, with 50% achieving ATD-free remission.
Registrational Trials
Two trials for IMVT-1402 in Graves' disease are ongoing, aiming for topline readouts in 2027.
- The six-month remission data indicates strong durability of response and potential practice-changing implications for physicians.
- Safety and tolerability of batoclimab remain consistent with prior studies, adding to its positive profile as a potential treatment for Graves' disease.
Immunovant's groundbreaking findings in Graves' disease treatment mark a significant advancement in addressing the unmet needs of patients. The potential for disease modification and improved remission rates highlight the transformative impact of batoclimab in this study.